HomeCompareAIVI vs PFE

AIVI vs PFE: Dividend Comparison 2026

AIVI yields 4.42% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $22.9K in total portfolio value· pulled ahead in Year 9
10 years
AIVI
AIVI
● Live price
4.42%
Share price
$54.12
Annual div
$2.39
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.7K
Annual income
$586.90
Full AIVI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AIVI vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIVIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIVI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIVI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIVI
Annual income on $10K today (after 15% tax)
$375.76/yr
After 10yr DRIP, annual income (after tax)
$498.86/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,821.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIVI + PFE for your $10,000?

AIVI: 50%PFE: 50%
100% PFE50/50100% AIVI
Portfolio after 10yr
$38.1K
Annual income
$13,422.81/yr
Blended yield
35.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AIVI
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIVI buys
0
PFE buys
0
No recent congressional trades found for AIVI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIVIPFE
Forward yield4.42%6.13%
Annual dividend / share$2.39$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$26.7K$49.6K
Annual income after 10y$586.90$26,258.71
Total dividends collected$5.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AIVI vs PFE ($10,000, DRIP)

YearAIVI PortfolioAIVI Income/yrPFE PortfolioPFE Income/yrGap
1$11,142$442.07$9,153$693.39+$2.0KAIVI
2$12,382$460.34$8,593$849.25+$3.8KAIVI
3$13,727$478.11$8,336$1,066.78+$5.4KAIVI
4$15,184$495.37$8,437$1,384.80+$6.7KAIVI
5$16,758$512.07$9,013$1,875.40+$7.7KAIVI
6$18,460$528.21$10,306$2,680.72+$8.2KAIVI
7$20,296$543.77$12,820$4,101.38+$7.5KAIVI
8$22,275$558.74$17,673$6,826.70+$4.6KAIVI
9← crossover$24,407$573.12$27,543$12,591.86$3.1KPFE
10$26,703$586.90$49,560$26,258.71$22.9KPFE

AIVI vs PFE: Complete Analysis 2026

AIVIStock

The fund is actively managed and seeks to invest primarily in equity securities selected from a universe of developed market equities, excluding the United States and Canada, that exhibit value characteristics based on the selection results of a proprietary, quantitative artificial intelligence (“AI”) model developed by Sub-Adviser. The equity securities selected by the AI model typically have a lower price-to-book ratio, a lower price-to-earnings ratio, and greater free cash flow. The fund is non-diversified.

Full AIVI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AIVI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIVI vs SCHDAIVI vs JEPIAIVI vs OAIVI vs KOAIVI vs MAINAIVI vs JNJAIVI vs MRKAIVI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.